The Reduction of Tau Hyperphosphorylation by Cornel Iridoid Glycosides Is Mediated by Their Influence on Calpain Activity

Kaiwen Guo, Cuicui Yang, and Lan Zhang ©

Department of Pharmacy, Xuanwu Hospital of Capital Medical University,
National Clinical Research Center for Geriatric Diseases, Beijing Engineering Research Center for Nervous System Drugs,
Beijing Institute for Brain Disorders, Key Laboratory for Neurodegenerative Diseases of Ministry of Education,
45 Chang-Chun Street, Beijing 100053, China

Correspondence should be addressed to Lan Zhang; xwzhanglan@126.com

Received 14 June 2021; Revised 11 November 2021; Accepted 8 December 2021; Published 20 January 2022

Academic Editor: Md. Sahab Uddin

Copyright © 2022 Kaiwen Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alzheimer’s disease (AD) is the most common type of dementia, and the abnormal hyperphosphorylation of the tau protein is the main component of its pathogenesis. Calpain was found to be abnormally activated in neurofibrillary tangles (NFTs) in a previous report. Cornel iridoid glycosides (CIG) have been reported to reduce the hyperphosphorylation of tau protein. Nevertheless, the role of calpain in the reduction tau hyperphosphorylation by CIG remains unclear. In the present study, we investigated the effect of CIG on calpain activity through in vitro and in vivo experiments. Western blotting results suggested that CIG decreased the phosphorylation of tau at Ser 404 and Ser 262 sites in P301S mice. Moreover, CIG inhibited the activity of calpain and glycogen synthase kinase 3β (GSK-3β) and enhanced the activity of protein phosphatase 2A (PP2A) both in vivo and in vitro. CIG also inhibited the activation of PP2A and reduced the GSK-3β activity caused by the calpain activator dibucaine. In addition, the main components of CIG, morroniside and loganin, play an equivalent role in reducing calpain activity, as the effect of their combined use is equivalent to that of CIG. The abovementioned findings revealed that CIG improved PP2A activity and reduced GSK-3β activity by adjusting the activity of calpain 1, leading to a reduction in the phosphorylation of tau. This study highlights the remarkable therapeutic potential of CIG for managing AD.

1. Introduction

The hyperphosphorylation of the tau protein causes microtubule breakdowns, leading to neuronal conduction system disorders and the formation of neurofibrillary tangles (NFTs), causing cognitive impairment [1, 2].

Reports analyzing stained brain tissue from Alzheimer’s disease (AD) patients found that neurons containing NFTs showed high expression levels of the protein calpain [3]. The calpain family has 15 members; calpain 1 plays an important role in the activation of glycogen synthase kinase 3β (GSK-3β) and protein phosphatase 2A (PP2A) [4–6], and calpain 2 can also regulate the activity of PP2A [7]. Calpastatin, a calpain inhibitor, is the only endogenous specific calcium-activated neutral protease family inhibitor; calpain activity is strictly regulated by calpastatin in the presence of Ca2+ [8]. Alicipstat is a new drug being developed to treat AD by inhibiting calpain 1/2 activity, and trials were terminated due to inadequate CNS concentrations to obtain a pharmacodynamic effect [9]. Therefore, calpain may be a new target for AD treatment.

The phosphorylation of tau is regulated by phosphokinases and phosphatases [10]. PP2A is a serine/threonine protein phosphatase that dephosphorylates proteins in eukaryotes; the activity of PP2A in the brains of patients with AD is reduced significantly [11]. GSK-3 is a serine/threonine phosphokinase that is widely distributed in living organisms; GSK-3β is considered a key player in tau phosphorylation [12], and inhibiting its activity may revert learning and memory impairment [13]. The activities of GSK-3β and PP2A are influenced by calpain.
Cornel iridoid glycoside (CIG) was found in the literature to significantly inhibit abnormal hyperphosphorylation of tau protein, protect the structure of neuronal microtubules, reduce the formation of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofilament phosphorylation of tau protein, protect the structure of neurofibrillary tangles, and increase the number of surviving neuronal microtubules, reduce the formation of neurofib...
Figure 1: Effects of treatment with CIG on protein tau phosphorylation. (a) CIG reduced tau protein phosphorylation in P301S mice. P301S mice were treated with CIG and MEM everyday for 3 months. The expression of phosphorylation of tau at (b) Ser404, (c) Ser262, and GAPDH in P301S mice is shown. (d) The expression of phosphorylation of GSK-3β at (e) Ser9, (f) N-terminal of GSK-3β (11B9), (g) GSK-3β 27C10, and (h) PP2A-c in P301S mice is shown. Mean ± SEM, n = 4; *p < 0.05, **p < 0.01, ***p < 0.001, compared with the nTg group; #p < 0.05, ##p < 0.01, compared with the P301S group. CIG (L): 50 mg/kg, CIG (M): 100 mg/kg, and CIG (H): 200 mg/kg. MEM: memantine; CIG: cornel iridoid glycosides; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; GSK-3β: glycogen synthase kinase 3β; and PP2A: protein phosphatase 2A.
Figure 2: Effects of treatment with CIG on calpain activity. (a) CIG reduced calpain activity in P301S mice and MAPT cells. The expression of (b) calpain 1, (c) calpain 2, (d) spectrin, and GAPDH in P301S mice is shown. Mean ± SEM, n = 4; *p < 0.05, compared with the nTg group; #p < 0.05, ##p < 0.01, compared with the P301S group. MAPT cells were treated with CIG for 24 hours. (e) The expression of (f) calpain 1, (g) calpain 2, (h) spectrin, and GAPDH in MAPT cells is shown. Mean ± SEM, n = 3; *p < 0.05, compared with the N2a group; #p < 0.05, compared with the MAPT group. CIG (L): 50 μg/mL, CIG (M): 100 μg/mL, CIG (H): 200 μg/mL, CIG: cornel iridoid glycosides, MAPT: microtubule-associated protein tau, and GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
an important calpain activation marker, was significantly reduced after CIG administration (Figure 2(a)).

3.3. CIG Inhibited Calpain Activity in MAPT-Overexpressed N2a Cells. To verify whether CIG can reduce the activity of calpain, we used N2a cells with overexpressed MAPT for further experiments. N2a, MAPT, and CIG (50, 100, and 200 μg/mL)-treated MAPT cells were used to detect the expression levels of calpain 1, calpain 2, and spectrin αII. As shown in Figure 2(e), calpain 1 and calpain 2 expression levels were significantly lower in high-dose CIG-treated cells than in MAPT cells. Cleavage of spectrin αII was decreased in the CIG-treated group compared to that in the model group (Figure 2(e)).

Taken together, these results indicate that CIG effectively attenuated calpain activity both in vivo and in vitro.

3.4. Morroniside and Loganin Inhibited Calpain Activity in MAPT-Overexpressed N2a Cells. Morroniside and loganin account for 70% of the effective ingredients of CIG. To verify if morroniside and loganin monomers alone would have the same effect as CIG, we examined the calpain inhibition effect of these components in isolation and in combination. MAPT cells that were treated with morroniside and loganin showed results equivalent to those found for medium-dose CIG (100 μg/mL). Morroniside, loganin, and CIG at different concentrations were found to reduce the ratio (150 kDa/250 kDa) of spectrin αII caused by MAPT overexpression, which led to a decrease in calpain activity (Figure 3(a)). In combination, morroniside coordinated with loganin to reduce the high expression level of calpain 1 induced by MAPT overexpression (Figure 3(a)). SDS-PAGE results revealed that the previously low expression level of p-GSK-3β was significantly increased by the administration of CIG, morroniside, and loganin treatment (Figure 3(d)). Moreover, it was found that the activity of PP2A had significantly increased following treatment with morroniside, loganin, and CIG (Figure 3(f)).

3.5. Effect of CIG on Calpain, GSK-3β, and PP2A Activity in Calpain-Activated N2a Cells. Dibucaine is a known activator of calpain, and N2a cells treated with dibucaine were used to investigate whether CIG could reduce the activation of calpain in N2a cells under this condition. We observed that, after treating N2a cells with dibucaine for 6 h, spectrin αII was truncated, which was reverted after the administration of CIG and its main components, morroniside and loganin (Figure 4(a)). However, there was no change in the expression levels of calpain 1/2 and PP2A in each group (Figure 4(a)). SDS-PAGE results revealed that the dibucaine-induced low expression of p-GSK-3β was not significantly increased by the administration of CIG, morroniside, and loganin treatment (Figure 4(a)). In addition, compared with vehicle-treated N2a cells, PP2A activity was significantly decreased in dibucaine-treated N2a cells. The activity of PP2A was enhanced after the administration of CIG, morroniside, and loganin (Figure 4(f)).

4. Discussion

Studies have found an increase in the activation of calpain in the brain of patients with Alzheimer’s disease (AD) [15–17]. In animal models of AD, inhibition of calpain 1 and 2 restores normal synaptic function and cognitive behavior and decreases amyloid plaques [18]. Inhibitors of calpain diminish the hyperphosphorylation of tau [19]. This experiment showed that CIG and its active ingredients morroniside and loganin could reduce tau hyperphosphorylation by regulating the activity of calpain.

The hyperphosphorylation of tau protein is recognized as one of the main pathogenic mechanisms of AD [20], being positively correlated with the degree of cognitive dysfunction. The microtubule-associated protein tau (MAPT) is P301S mice model was used in this study because it exhibits brain activation of glycogen synthase kinase 3β (GSK-3β), protein phosphatase 2A (PP2A) activity inhibition, and protein tau hyperphosphorylation; the phosphorylation of tau is regulated by GSK-3β and PP2A. In this study, CIG reduced the activation of GSK-3β and enhanced the activation of PP2A in P301S mice and MAPT-overexpressing N2a cells. These results are consistent with those of previous observational studies, in which CIG could regulate tau phosphorylation by kinase activity [21].

GSK-3β is reported to be the primary tau kinase activated by calpain [6]. GSK-3β activity can be regulated by phosphorylation and through the truncation of GSK-3β. A previous study described N-terminal proteolysis as a novel way to regulate GSK-3β, and calpain inhibitors can prevent this truncation [6, 22]. In this study, we found that CIG could improve the phosphorylation of GSK-3β at site Ser 9. This is similar to the results of a previous study. We also found that the N-terminal cleavage of GSK-3β was improved after CIG administration. However, this result has not been previously described; previous studies have found that the truncation of GSK-3β at the N-terminus was not regulated by calpain [23]. A possible explanation for this divergence is that the N-terminal truncation of GSK-3β was not stable, and the product was rapidly degraded in in vitro experiments.

PP2A accounts for most of the dephosphorylation activities of tau protein [24]. Calpain is also shown to mediate the activity of the PP2A [4, 25]. In accordance with the present results, previous studies have demonstrated that CIG regulates the influence of calpain on PP2A activity. The activity of calpain in the cerebrospinal fluid of patients with AD is significantly increased [26]. We found high calpain activity in P301S mice and the MAPT cell line. Consistent with the literature, this study found that CIG led to the activation of calpain activity, as revealed by the almost complete loss of 250 kDa full-length spectrin protein and the appearance of a major 150 kDa spectrin cleavage product that is specific to calpain activity [27, 28].

These Ca2+-regulated protease calpains, both 1 and 2, were abnormally activated and abnormally high in the brains of patients with AD. In this study, we found that calpain 1 in the model group (P301S/MAPT) was significantly higher than that in the normal group (n1g/N2a). These results
support those of previous studies. However, calpain 2 did not show this tendency. Gffi_his result may be explained by the fact that calpain 2 may have a role in a reaction in which calpain 1 does not participate [29].

Morroniside and loganin are the main components of CIG. To explore their effect on calpain, the cells were treated with the monomers in isolation and their combination. Morroniside attenuates okadaic acid- (OA-) induced tau hyperphosphorylation via PP2A activation [30]. Loganin has been found to exhibit significant neuroprotective effects and the ability to slow down the process of neurogenesis in AD [31]. We found that morroniside and loganin act on MAPT cells alone. They can inhibit the activity of GSK-3β and enhance the activity of PP2A, but there was no significant difference compared to the model group. When morroniside and loganin are used in combination, it can significantly reduce the activity of GSK-3β and enhance the activity of PP2A, with results equivalent to those of CIG. Gffi_he activator of calpain, dibucaine, can activate calpain 1 and calpain 2 in cells [32–34]. We used this cell model and found that CIG, morroniside, and loganin could reduce the calpain activity induced by dibucaine. However, the expression of calpain 1

**Figure 3:** Effects of morroniside and loganin treatment on calpain activity. (a) CIG, morroniside, and loganin alleviated the activation of calpain in MAPT cells. The expression of (b) calpain 1, (c) spectrin α II, (e) phosphorylation of GSK-3β at Ser 9, and GAPDH in MAPT cells was determined by western blot and semiquantitative analysis. (f) The activity of PP2A in MAPT cells. Mean ± SEM, n = 3; *p < 0.05, compared with the N2a group; #p < 0.05, compared with the MAPT group. CIG (M): 100 μg/mL, CIG (H): 200 μg/mL, MOR: morroniside (240 μM), LOG: loganin (120 μM), ML: morroniside (240 μM) and loganin (120 μM), CIG: cornel iridoid glycosides, and MAPT: microtubule-associated protein tau.
calpain 1 did not change. We also found that the combined use of morroniside and loganin has a better effect than that of the isolated components, with results equivalent to those of CIG. This suggests that morroniside and loganin may have an internal interaction; therefore, their combined use can enhance efficacy.

The results indicate that CIG can regulate its downstream signals GSK-3β and PP2A by regulating calpain activity to reduce the hyperphosphorylation of tau protein.

In conclusion, this paper describes the useful effects of CIG and its main components, morroniside and loganin, which could reduce tau phosphorylation through the calpain 1/GSK-3β/PP2A pathway. The present study provides new ideas for the development of drugs to revert tau hyperphosphorylation, one of the main pathological mechanisms of AD.

Data Availability

Data used to support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.
Acknowledgments

This study was supported by a grant from the National Natural Science Foundation of China (No. 81874351). It was also supported by the Beijing Hospitals Authority Ascent Plan (DFL20190803), Capital Science and Technology Leading Talent Training Project (Z19110006190107), and National Major Science and Technology Projects of China (No. 2015ZX09101-016). It was also supported by a grant from the National Natural Science Foundation of China (No.81874351). It was also supported by the Beijing Hospitals Authority Ascent Natural Science Foundation of China (No.81874351).

References

[1] L. Aragão Gomes, V. Uytterhoeven, D. Lopez-Sammartin et al., "Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation," Acta Neuropathologica, vol. 141, no. 2, pp. 173–192, 2021.

[2] R. Medeiros, D. Baglietto-Vargas, and F. M. LaFerla, "The role of tau in Alzheimer’s disease and related disorders," CNS Neuroscience & Therapeutics, vol. 17, no. 5, pp. 514–524, 2011.

[3] A. Ferreira, "Calpain dysregulation in Alzheimer’s disease," ISRN Biochemistry, vol. 2012, pp. 1–12, 2012.

[4] N. Jin, Y. Wu, W. Xu, C. X. Gong, K. Iqbal, and F. Liu, "C-terminal truncation of GSK-3β enhances its dephosphorylation by PP2A," FEBS Letters, vol. 591, no. 7, pp. 1053–1063, 2017.

[5] Y. Feng, Y. Xia, G. Yu et al., "Cleavage of GSK-3β by calpain counteracts the inhibitory effect of Ser9 phosphorylation on GSK-3β activity induced by H2O2," Journal of Neurochemistry, vol. 126, no. 2, pp. 234–242, 2013.

[6] S. Ma, S. Liu, Q. Huang et al., "Site-specific phosphorylation protects glycogen synthase kinase-3β from calpain-mediated truncation of its N and C termini," Journal of Biological Chemistry, vol. 287, no. 27, pp. 22521–22532, 2012.

[7] V. Janssens, R. Derua, K. Zwaenepoel, E. Waelkens, and J. Goris, "Specific regulation of protein phosphatase 2A PR72/90 subunits by calpain," Biochemical and Biophysical Research Communications, vol. 386, no. 4, pp. 667–671, 2009.

[8] R. A. Hanna, R. L. Campbell, and P. L. Davies, "Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin," Nature, vol. 456, no. 7220, pp. 409–412, 2008.

[9] H. K. Lon, N. Mendonca, S. Goss et al., "Pharmacokinetics, safety, tolerability, and pharmacodynamics of alicapastat, a selective inhibitor of human calpains 1 and 2 for the treatment of Alzheimer’s disease: an overview of phase 1 studies," ISRN Biochemistry Communications, vol. 2012, pp. 1–12, 2012.

[10] P. Goñi-Oliver, J. J. Lucas, J. Avila, and F. Hernández, "N-terminal cleavage of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation via regulating cross-talk between GSK-3β and PP2A signaling," Frontiers in Pharmacology, vol. 9, p. 682, 2018.

[11] Y. Wang, V. Briz, A. Chishti, X. Bi, and M. Baudry, "Distinct roles for –calpain and m-calpain in synaptic NMDAR-mediated neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration," Journal of Neuroscience, vol. 33, no. 48, pp. 18880–18892, 2013.

[12] C. Yang, X. Li, W. Gao et al., "Cornel iridoid glycoside inhibits tau hyperphosphorylation via regulating cross-talk between GSK-3β and PP2A signaling," Frontiers in Pharmacology, vol. 9, p. 682, 2018.

[13] P. K. Kamat, S. Rai, S. Swarnkar et al., "Okadaic acid-induced tau phosphorylation in rat brain: role of NMDA receptor," Neuroscience, vol. 238, pp. 97–113, 2013.

[14] C. Laske, K. Stellos, J. Kempter et al., "Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer’s disease," Alzheimer’s & Dementia, vol. 11, no. 5, pp. 465–474, 2015.

[15] J. Jiang, C. Shao, F. Tang, W. Wang, and X. Zhu, "Dynamin-like protein 1 cleavage by calpain in Alzheimer’s disease," Aging Cell, vol. 18, no. 3, Article ID e12912, 2019.

[16] C. Descloux, V. Ginet, C. Rummel, A. C. Truttmann, and J. Puyal, "Enhanced autophagy contributes to excitotoxic lesions in a rat model of preterm brain injury," Cell Death & Disease, vol. 9, no. 9, p. 853, 2018.

[17] C. Ciricoglu, T. M. Satir, G. Brinkmalm et al., "Tauopathy-associated tau fragment ending at amino acid 224 is generated by calpain-2 cleavage," Journal of Alzheimer’s Disease, vol. 74, no. 4, pp. 1143–1156, 2020.
[30] C. C. Yang, X. X. Kuai, W. B. Gao et al., "Morroneide-induced PP2A activation antagonizes tau hyperphosphorylation in a cellular model of neurodegeneration," *Journal of Alzheimer’s Disease*, vol. 51, no. 1, pp. 33–44, 2016.

[31] B. Dinda, M. Dinda, G. Kulsi, A. Chakraborty, and S. Dinda, "Therapeutic potentials of plant iridoids in alzheimer’s and parkinson’s diseases: a review," *European Journal of Medicinal Chemistry*, vol. 169, pp. 185–199, 2019.

[32] P. Zhang, J. Du, L. Zhao et al., "The role of intraplatelet reactive oxygen species in the regulation of platelet glycoprotein Ibα ectodomain shedding," *Thrombosis Research*, vol. 132, no. 6, pp. 696–701, 2013.

[33] W. Zhang, J. Liu, R. Sun et al., "Calpain activator dibucaine induces platelet apoptosis," *International Journal of Molecular Sciences*, vol. 12, no. 4, pp. 2125–2137, 2011.

[34] Z. Wang, Q. Shi, R. Yan, G. Liu, W. Zhang, and K. Dai, "The role of calpain in the regulation of ADAM17-dependent GPIbα ectodomain shedding," *Archives of Biochemistry and Biophysics*, vol. 495, no. 2, pp. 136–143, 2010.